HFrEF 联合 CCM 和 ICD 装置的评估 (INTEGRA-D)
联合心脏收缩力调制和植入式心律转复除颤器装置对心力衰竭和射血分数降低患者的安全性和有效性评估
The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D System (the "CCM-D System") can safely and effective convert induced ventricular fibrillation (VF) and spontaneous ventricular tachycardia and/or ventricular fibrillation (VT/VF) episodes in subjects with Stage C or D heart failure who remain symptomatic despite being on guideline-directed medical therapy (GDMT), are not indicated for cardiac resynchronization therapy (CRT), and have heart failure with reduced left ventricular ejection fraction (LVEF ≤40%).
Eligible subjects will be implanted with the CCM-D System. A subset of subjects will be induced into ventricular fibrillation "on the table" in the implant procedure room. During the follow-up period, inappropriate shock rate and device-related complications will be evaluated. The follow-up period is expected to last at least two years.
研究概览
地位
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Arizona
-
Glendale、Arizona、美国、85306
- Phoenix Heart
-
Mesa、Arizona、美国、85208
- Southwest Cardiovascular Associates
-
Mesa、Arizona、美国、85206
- CardioVascular Associates of Mesa
-
Phoenix、Arizona、美国、85016
- Arizona Heart Rhythm
-
Phoenix、Arizona、美国、85032
- CVC Cardiovascular Consultants
-
Phoenix、Arizona、美国、85306
- Phoenix Heart
-
Scottsdale、Arizona、美国、85258
- Honor Health
-
-
California
-
Los Angeles、California、美国、90033
- University of Southern California
-
Los Angeles、California、美国、90048
- Cedars Sinai Medical Center
-
-
Connecticut
-
Hartford、Connecticut、美国、06102
- Hartford HealthCare
-
-
Florida
-
Fort Lauderdale、Florida、美国、33316
- Broward Health Medical Center
-
Miami、Florida、美国、33173
- Baptist Health South Florida
-
Miami Beach、Florida、美国、33140
- Mount Sinai Medical Center Miami Beach
-
Orlando、Florida、美国、32803
- Advent Health Orlando
-
-
Iowa
-
West Des Moines、Iowa、美国、50266
- Iowa Heart Center
-
-
Kansas
-
Kansas City、Kansas、美国、66103
- University of Kansas Medical Center
-
-
Kentucky
-
Lexington、Kentucky、美国、40503
- Baptist Health Lexington
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- Massachusetts General Hospital
-
-
Missouri
-
Kansas City、Missouri、美国、64111
- Saint Luke's Hospital
-
St Louis、Missouri、美国、63136
- St. Louis Heart and Vascular
-
St Louis、Missouri、美国、63106
- St. Louis VA
-
-
New Jersey
-
Browns Mills、New Jersey、美国、08015
- Deborah Heart and Lung Center
-
Cherry Hill、New Jersey、美国、08034
- Virtua
-
Hackensack、New Jersey、美国、07601
- Hackensack University Medical Center
-
Haddon Heights、New Jersey、美国、08035
- The Heart House - Cardiovascular Associates of the Delaware Valley
-
Newark、New Jersey、美国、07103
- Rutgers New Jersey Medical School
-
-
New York
-
New York、New York、美国、10065
- Weill Cornell Medicine
-
New York、New York、美国、10016
- NYU Langone
-
New York、New York、美国、10029
- Mount Sinai New York
-
New York、New York、美国、10032
- Columbia University Medical Center / NewYork-Presbyterian
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27599
- University of North Carolina
-
Charlotte、North Carolina、美国、28277
- Sanger Heart and Vascular Institute
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- Cleveland Clinic
-
Cleveland、Ohio、美国、44106
- Louis Stokes Cleveland VA Medical Center
-
Columbus、Ohio、美国、43210
- The Ohio State University Wexner Medical Center
-
-
Oklahoma
-
Tulsa、Oklahoma、美国、74136
- St. Francis Tulsa
-
-
Oregon
-
Portland、Oregon、美国、97239
- Portland VA Medical Center
-
-
Pennsylvania
-
Bethlehem、Pennsylvania、美国、18015
- St. Luke's Bethlehem
-
Bryn Mawr、Pennsylvania、美国、19010
- Bryn Mawr Medical Specialists Association
-
Lancaster、Pennsylvania、美国、17602
- Lancaster General Hospital
-
Philadelphia、Pennsylvania、美国、19140
- Temple University
-
Philadelphia、Pennsylvania、美国、19104
- Penn Presbyterian
-
Pittsburgh、Pennsylvania、美国、15212
- Allegheny General Hospital
-
Pittsburgh、Pennsylvania、美国、15219
- University of Pittsburgh Medical Center
-
-
South Carolina
-
Greenville、South Carolina、美国、29601
- Prisma Health
-
-
Tennessee
-
Germantown、Tennessee、美国、38138
- Stern Cardiovascular Foundation
-
-
Texas
-
Austin、Texas、美国、78705
- Texas Cardiac Arrhythmia Research Foundation
-
Dallas、Texas、美国、75230
- Medical City Dallas
-
Dallas、Texas、美国、75390
- UT Southwestern
-
Fort Worth、Texas、美国、76104
- Medical City Fort Worth
-
Houston、Texas、美国、77030
- Houston Methodist
-
Houston、Texas、美国、77030
- Houston VA Hospital
-
Houston、Texas、美国、77030
- UT Memorial Hermann
-
Tyler、Texas、美国、75702
- Christus Trinity Clinic
-
-
Virginia
-
Lynchburg、Virginia、美国、24501
- Centra Health
-
Richmond、Virginia、美国、23298
- Virginia Commonwealth University
-
Richmond、Virginia、美国、23225
- Chippenham Hospital
-
-
Washington
-
Seattle、Washington、美国、98122
- Swedish
-
Seattle、Washington、美国、98108
- Seattle VA
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Individuals must meet all the following:
- Patient is aged 18 years or older;
- Patient meets the Stage C or D criteria of the Universal Definition of Heart Failure ;
- Patient has HFrEF (LVEF ≤40%);
- Patient is on GDMT for heart failure;
- Patient has a Class I or Class II indication for an ICD
- Patient has a reasonable expectation of meaningful survival of > 1 year;
- Patient has either non-ischemic cardiomyopathy or ischemic cardiomyopathy and is at least 40 days post-MI, if an MI occurred;
- Patient is willing to give informed consent, available for scheduled study follow-up visits, and able to complete all testing described in the study protocol at the investigational site location.
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Patients should not have severe AI or AS, and should not have MS; additionally, patients undergoing DE testing should not have severe MR;
- Patients who have undergone mitral valve repair or clip within 90 days prior to study consent;
- Cardiac surgery within 90 days or a PCI procedure within 30 days prior to study consent;
- Prior heart transplant or ventricular assist device;
- Implanted mechanical tricuspid valve;
- PR interval greater than 375ms or advanced AV block;
- In situ S-ICD, pacemaker, or CRT device;
- Indicated for CRT;
- End stage renal disease, currently on dialysis, or with other major medical disorder (e.g. liver failure, terminal cancer);
- Indicated for permanent bradyarrhythmia pacing;
- Unstable angina pectoris within 30 days prior to study consent;
- Pregnant or planning to become pregnant during the study;
- Participating in another cardiac investigational device or drug study at the same time (or within 30 days prior to study consent); Note: Registries and other observational studies are acceptable.
- Other criteria that preclude Optimizer INTEGRA CCM-D implantation and/or CCM therapy, as determined by Investigator.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:CCM-D Implant
The subject is implanted with the CCM-D device. |
The CCM-D System is an implantable cardiac device system that combines cardiac contractility modulation and implantable cardioverter defibrillator (ICD) modules into one device. CCM-D is also known as a "Cardiac Contractility Modulation - Defibrillator". All 300 subjects will be implanted with the CCM-D System and followed for a period of at least two years. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Device Effectiveness in Converting Induced Ventricular Fibrillation (Primary Efficacy Objective)
大体时间:Implant
|
Evaluate the device effectiveness in converting induced VF at the time of implantation. |
Implant
|
|
Device-related Complications (Primary Safety Objective)
大体时间:Implant to 6 months
|
Evaluate device-related complications through 6-months (excluding lead-related complications). |
Implant to 6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Inappropriate Shock Rate out to 6-months (Secondary Safety Objective)
大体时间:Implant to 6 months
|
Evaluate the incidence of inappropriate ICD shocks through the time when the last subject enrolled completes the 6-month visit. |
Implant to 6 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Inappropriate Shock Rate out to 2-years
大体时间:Implant to 2 years
|
Evaluate the device effectiveness in converting spontaneous VT/VF through the time when the last subject enrolled completes the 6-month visit. Each subject will be followed for 2-years after implant to capture additional spontaneous episodes that may occur. |
Implant to 2 years
|
|
Charging non-compliance
大体时间:Implant to 2 years
|
Evaluate subject charging non-compliance defined as >14 days between interval charging sessions, overall and frequency of non-compliance in the same subject. |
Implant to 2 years
|
|
Longitudinal levels of activity
大体时间:Implant to 2 years
|
Track longitudinal levels of activity weekly via OPTIhome (when available) and identification of trends. |
Implant to 2 years
|
|
Battery degradation and longevity
大体时间:Implant to 2 years
|
Assess battery degradation and longevity either remotely or during an in-person follow-up at 2 years (+/- 60 days) by recording QHR battery voltage as measured by the Integra CCM-D IPG. The measurement under nominal conditions is expected to be 2.85V or higher, consistent with a 20-year device longevity. |
Implant to 2 years
|
|
Compare worsening heart failure events pre- and post-implant
大体时间:12 months prior to implant and 12 months post-implant
|
Track unscheduled cardiovascular-related healthcare encounters from 12 months prior to implant, if available, to 12 months post-implant |
12 months prior to implant and 12 months post-implant
|
|
All-cause mortality
大体时间:1 and 2 years post-implant
|
Assess all-cause mortality using Seattle Heart Failure Model (SHFM) and comorbidity burden as a predictive comparator at 1 year and 2 years post-implant |
1 and 2 years post-implant
|
|
Kansas City Cardiomyopathy Questionnaire (KCCQ)
大体时间:Baseline to 6-months
|
Compare change in subject's perception of their heart failure symptoms, as measured by KCCQ, from baseline to 6 months. |
Baseline to 6-months
|
|
EQ-5D-5L
大体时间:Baseline to 6-months
|
Compare change in subject's perception of their health status, as measured by the EQ-5D-5L, from baseline to 6 months. |
Baseline to 6-months
|
|
Six Minute Walk Distance (6MWD)
大体时间:Baseline to 6 months
|
Compare change in functional capacity, as measured by 6MWD, from baseline to 6 months. |
Baseline to 6 months
|
合作者和调查者
调查人员
- 首席研究员:Nir Uriel, MD、Columbia University
- 首席研究员:Niraj Varma, MD, PhD、The Cleveland Clinic
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.